AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010, for Hemispherx Biopharma, Inc. The company is a specialty pharmaceutical firm focused on the clinical development of immune system-enhancing therapies, primarily Ampligen (for Chronic Fatigue Syndrome) and Alferon N Injection (for genital warts). The company operates a manufacturing facility in New Jersey and is currently in a pre-commercialization phase for its primary pipeline products, relying on cost-recovery programs for revenue.

Key Financial Metrics

Note: The filing text does not provide explicit margin percentages due to negligible revenue relative to expenses. The company has no long-term debt other than a minor capital lease obligation of $65,000.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $957,000 (31%) compared to Q1 2009. This was driven by a 25% increase in R&D expenses ($401,000 increase) and a 69% increase in General and Administrative (G&A) expenses ($803,000 increase).
• Expense Drivers: The surge in G&A expenses was primarily due to an additional $769,000 in legal fees related to defending three active legal proceedings. R&D increases were attributed to preparing a response to the FDA's Complete Response Letter (CRL) for Ampligen and advancing Alferon LDO clinical preparations.
• Financing Costs: Financing costs decreased by $241,000 as the Standby Financing Agreement executed in 2009 was no longer incurring costs in the current period.
• Liquidity: Cash and cash equivalents decreased by $7.3 million during the quarter, largely due to operating burn and the purchase of $3.1 million in short-term marketable securities.

Guidance, Outlook, and Risks

Regulatory Status:

• Ampligen: Received a Complete Response Letter (CRL) from the FDA in November 2009. The FDA determined the application could not be approved in its present form, citing a lack of credible evidence of efficacy in primary studies. The FDA recommended at least one additional clinical study with at least 300 patients, a duration of six months, and specific safety monitoring (including QT interval studies and rodent carcinogenicity studies).
• Alferon LDO: A proposed Phase 2 clinical study for influenza is currently on "Clinical Hold" by the FDA due to deficiencies in protocol design and Chemistry, Manufacturing, and Controls (CMC) issues, specifically regarding the stability of drug lots manufactured from 2001 API.
• Alferon N Injection: Commercial sales remain halted due to expired inventory. Manufacturing upgrades are underway, with potential availability for commercial sales projected for mid-to-late 2011.

• The company is defending against multiple lawsuits, including a securities class action and shareholder derivative suits alleging misrepresentation regarding the Ampligen NDA status.
• Other active litigation includes disputes with MidSouth Capital (counterclaim for fees) and Cato Capital (placement fee dispute seeking up to $9.8 million).

• The company has an accumulated deficit of approximately $215 million and expects to continue incurring substantial losses.
• Future profitability is uncertain and dependent on regulatory approval and commercialization. The company may need to seek additional equity financing, which could result in significant dilution.

Investor Verification Checklist

• FDA Response Strategy: Verify the specific timeline and cost estimates for the additional clinical study required by the FDA for Ampligen approval.
• Legal Exposure: Monitor the status of the securities class action and the Cato Capital lawsuit, as adverse outcomes could materially impact financial condition.
• Manufacturing Timeline: Confirm the progress of the capital improvement program at the New Brunswick facility and the feasibility of the mid-to-late 2011 restart date for Alferon N Injection sales.
• Cash Runway: Assess the sufficiency of the $50.7 million cash balance against the projected burn rate, considering the high legal and R&D costs.
• Authorized Shares: Note that the company failed to increase its authorized share count in 2009, potentially limiting its ability to raise capital via equity issuance without further shareholder approval.